Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 08:31 ET | Source: PolarityBio

PolarityBio Announces Acceptance of Category III CPT® Code Application for Autologous Heterogeneous Skin Construct Graft by AMA CPT® Editorial Panel

SALT LAKE CITY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative...
September 02, 2025 08:31 ET | Source: PolarityBio

PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE® for Patients with Wagner 1 Diabetic Foot Ulcers

PolarityBio announced the launch of an Expanded Access Treatment Protocol (EAP) to provide continued access to SkinTE® for patients.
August 28, 2025 08:31 ET | Source: PolarityBio

PolarityBio to Share Regenerative Wound Healing Expertise at SAWC Fall 2025

PolarityBio announced its participation in the Symposium on Advanced Wound Care (SAWC) Fall 2025.
August 26, 2025 08:31 ET | Source: PolarityBio

PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers

PolarityBio today announced the completion of patient enrollment in COVER DFUS II, a Pivotal Phase III Multicenter Randomized Controlled Trial (RCT).
February 20, 2025 08:30 ET | Source: PolarityBio

PolarityBio Receives U.S. FDA Breakthrough Therapy Designation for Treatment of Wagner Grade I Diabetic Foot Ulcers (DFU)

The FDA has granted Breakthrough Therapy Designation for SkinTE based on key positive data from the Phase II study in Wagner1 DFUs highlighting the ongoing unmet need in this patient populationFDA...
December 03, 2024 08:00 ET | Source: PolarityBio

PolarityBio Announces Interim Enrollment Achieved in SkinTE’s Phase III Pivotal Study

Interim Analysis Anticipated at end of Q1 2025 SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage biotechnology company developing regenerative tissue products, today...
May 20, 2024 08:00 ET | Source: Polarity TE

PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers

SALT LAKE CITY, May 20, 2024 (GLOBE NEWSWIRE) -- PolarityTE, a clinical-stage biotechnology company developing regenerative tissue products, today announced that it has raised $12.5 million in...
February 26, 2024 08:35 ET | Source: Polarity TE

PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

SALT LAKE CITY, Feb. 26, 2024 (GLOBE NEWSWIRE) -- PolarityTE today announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of...